Alnylam Pharmaceuticals
ALNY
#1148
Rank
HK$159.34 B
Marketcap
HK$1,190
Share price
-3.17%
Change (1 day)
-65.35%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): HK$9.56 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are HK$5.01 Billion. In 2025 the company made an earning of HK$5.60 Billion, an increase over its 2024 earnings that were of -HK$1.85 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) HK$9.56 B70.55%
2025 HK$5.60 B-403.41%
2024 -HK$1.85 Billion-24.59%
2023 -HK$2.46 Billion-67.84%
2022 -HK$7.62 Billion36.93%
2021 -HK$5.57 Billion-8.04%
2020 -HK$6.05 Billion-15.66%
2019 -HK$7.18 Billion12.23%
2018 -HK$6.4 Billion62.91%
2017 -HK$3.93 Billion17.78%
2016 -HK$3.34 Billion43.44%
2015 -HK$2.33 Billion60.69%
2014 -HK$1.45 Billion98.2%
2013 -HK$0.73 Billion
2011 -HK$0.44 Billion27.48%
2010 -HK$0.34 Billion-10.92%
2009 -HK$0.38 Billion95.77%
2008 -HK$0.2 Billion
2006 -HK$0.31 Billion-9.13%
2005 -HK$0.35 Billion34.74%
2004 -HK$0.26 Billion36.79%
2003 -HK$0.19 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
HK$99.18 B 935.08%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$61.09 B 537.61%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
HK$44.61 B 365.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-HK$1.03 Billion-110.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-HK$0.38 Billion-103.88%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-HK$1.25 Billion-113.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$9.60 B 0.21%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-HK$1.26 Billion-113.06%๐Ÿ‡บ๐Ÿ‡ธ USA